Profile data is unavailable for this security.
About the company
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.
- Revenue in USD (TTM)0.00
- Net income in USD-6.47m
- Incorporated2016
- Employees4.00
- LocationAlzamend Neuro Inc480 Peachtree Road NeSecond Floor, Suite 103ATLANTA 30326United StatesUSA
- Phone+1 (302) 636-5400
- Fax+1 (302) 636-5454
- Websitehttps://alzamend.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MetaVia Inc | 0.00 | -16.22m | 5.33m | 9.00 | -- | 0.5772 | -- | -- | -13.88 | -13.88 | 0.00 | 2.88 | 0.00 | -- | -- | 0.00 | -87.87 | -99.54 | -167.49 | -140.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -121.27 | -- | -48.18 | -- |
| Calidi Biotherapeutics Inc | 0.00 | -25.62m | 5.45m | 28.00 | -- | 0.7587 | -- | -- | -9.62 | -9.62 | 0.00 | 1.00 | 0.00 | -- | -- | 0.00 | -194.84 | -- | -1,279.90 | -- | -- | -- | -- | -- | -- | -58.24 | 0.1544 | -- | -- | -- | 18.49 | -- | -- | -- |
| Xenetic Biosciences Inc | 2.86m | -3.16m | 5.48m | 2.00 | -- | 0.9321 | -- | 1.92 | -2.05 | -2.05 | 1.85 | 2.57 | 0.436 | -- | -- | 1,429,470.00 | -48.14 | -42.99 | -57.42 | -46.44 | -- | -- | -110.40 | -373.71 | -- | -- | 0.00 | -- | -1.56 | 171.11 | 4.22 | -- | -- | -- |
| Alaunos Therapeutics Inc | 6.00k | -4.03m | 5.83m | 1.00 | -- | 2.05 | -- | 970.85 | -2.29 | -2.29 | 0.0034 | 1.27 | 0.0017 | -- | -- | 6,000.00 | -110.67 | -63.80 | -145.65 | -77.93 | -- | -- | -67,083.34 | -7,084.74 | -- | -- | 0.00 | -- | 100.00 | -- | 86.68 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 3.29m | -10.87m | 5.96m | 16.00 | -- | 1.23 | -- | 1.81 | -17.27 | -17.27 | 5.09 | 3.98 | 0.3025 | 2.74 | 5.08 | 205,752.50 | -100.21 | -73.55 | -191.77 | -123.30 | 43.08 | -- | -331.26 | -476.22 | 0.7618 | -- | 0.0392 | -- | -1.90 | 74.49 | -4.06 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -21.97m | 6.02m | 37.00 | -- | 0.1803 | -- | -- | -37.84 | -37.84 | 0.00 | 50.98 | 0.00 | -- | -- | 0.00 | -53.09 | -52.36 | -56.24 | -55.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.22 | -- | -36.69 | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -10.85m | 6.26m | 27.00 | -- | -- | -- | -- | -1.50 | -1.50 | 0.00 | -0.6973 | 0.00 | -- | -- | 0.00 | -637.06 | -112.30 | -- | -219.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 32.39 | -- | -- | -- |
| Alzamend Neuro Inc | 0.00 | -6.47m | 6.27m | 4.00 | -- | 1.43 | -- | -- | -5.71 | -5.71 | 0.00 | 1.15 | 0.00 | -- | -- | 0.00 | -116.49 | -171.97 | -144.76 | -256.71 | -- | -- | -- | -- | -- | -766.93 | 0.00 | -- | -- | -- | 48.68 | -- | -- | -- |
| Creative Medical Technology Holdings Inc | 6.00k | -5.96m | 6.40m | 4.00 | -- | 0.8445 | -- | 1,065.87 | -2.87 | -2.87 | 0.0027 | 2.17 | 0.0009 | 1.10 | -- | 1,500.00 | -93.58 | -83.62 | -98.14 | -- | 60.00 | 62.58 | -99,356.66 | -10,541.10 | 20.70 | -- | 0.00 | -- | 22.22 | -41.85 | -3.91 | -- | -- | -- |
| Theriva Biologics Inc | 0.00 | -26.19m | 6.44m | 22.00 | -- | 0.276 | -- | -- | -5.53 | -5.53 | 0.00 | 0.6539 | 0.00 | -- | -- | 0.00 | -73.83 | -37.94 | -99.55 | -42.02 | -- | -- | -- | -- | -- | -- | 0.2025 | -- | -- | -- | -39.81 | -- | -- | -- |
| Aptevo Therapeutics Inc | 0.00 | -27.95m | 6.58m | 37.00 | -- | 0.2907 | -- | -- | -306,220.00 | -306,220.00 | 0.00 | 22.67 | 0.00 | -- | -- | 0.00 | -125.64 | -47.17 | -172.77 | -82.66 | -- | -- | -- | -487.43 | -- | -- | 0.00 | -- | -- | -- | -29.38 | -- | -- | -- |
| Mustang Bio Inc | 0.00 | -2.34m | 6.64m | 6.00 | -- | 0.6796 | -- | -- | -47.37 | -47.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -17.59 | -70.16 | -224.95 | -83.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 69.47 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | -8.98m | 6.70m | 2.00 | -- | 0.1261 | -- | -- | -1.32 | -1.32 | 0.00 | 5.38 | 0.00 | -- | -- | 0.00 | -12.74 | 7.21 | -13.51 | 7.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 235.53 | -- | -- | -- |
| Aptorum Group Ltd | -100.00bn | -100.00bn | 6.94m | 1.00 | -- | 0.2701 | -- | -- | -- | -- | -- | 3.15 | -- | -- | -- | -- | -- | -33.06 | -- | -31.53 | -- | 1.65 | -- | -1,009.86 | -- | -- | 0.2079 | -- | -100.00 | -- | -51.09 | -- | -- | -- |
| Synlogic Inc | 0.00 | -3.23m | 7.28m | 1.00 | -- | 0.705 | -- | -- | -0.2625 | -0.2625 | 0.00 | 0.8826 | 0.00 | -- | -- | 0.00 | -17.30 | -44.41 | -27.54 | -50.06 | -- | -- | -- | -3,944.49 | -- | -- | 0.00 | -- | -99.76 | -67.55 | 61.88 | -- | -59.28 | -- |
Data as of Feb 13 2026. Currency figures normalised to Alzamend Neuro Inc's reporting currency: US Dollar USD
21.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| DRW Securities LLCas of 30 Sep 2025 | 91.25k | 11.39% |
| UBS Securities LLCas of 31 Dec 2025 | 24.57k | 3.07% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 21.02k | 2.62% |
| Geode Capital Management LLCas of 30 Sep 2025 | 20.58k | 2.57% |
| Clearstead Advisors, LLCas of 30 Sep 2025 | 10.00k | 1.25% |
| Tower Research Capital LLCas of 30 Sep 2025 | 1.61k | 0.20% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 600.00 | 0.08% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 437.00 | 0.06% |
| Bank of America, NA (Private Banking)as of 30 Sep 2025 | 26.00 | 0.00% |
| SBI Securities Co., Ltd.as of 31 Dec 2025 | 22.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
